莫西沙星治疗支原体肺炎疗效观察

Clinical efficacy of moxifloxacin in the treatment of Mycoplasma pneumonia

目的评价莫西沙星治疗支原体肺炎的临床疗效。方法在莫西沙星与阿奇霉素联合头孢曲松治疗社区获得性肺炎的随机对照临床研究中,对两组中诊断为支原体肺炎病例的疗效作对照分析。结果莫西沙星组和对照组有效率分别为96.4%、90.0%,细菌清除率分别为6/7和5/5,两组比较差异无统计学意义(P>0.05)。体温降至≤37.5℃所需时间和住院时间莫西沙星组(3.2±1.5)d和(8.2±1.7)d较对照组(4.4士1.7)d和(10.0±2.4)d明显缩短(P<0.05)。药物不良反应发生率莫西沙星组为14.3%,对照组为26.7%,两组比较差异无统计学意义(P>0.05)。结论对于支原体肺炎的治疗,莫西沙星单药治疗与阿奇霉素联合头孢曲松疗效相当,在缩短退热时间和住院时间方面莫西沙星优于对照组。

Objective To evaluate the clinical efficacy of moxifloxacin in the treatment of Mycoplasma pneumonia, Methods The clinical efficacy for Mycoplasma pneumonia was analyzed in a randomized, controlled clinical trial of moxifloxacin compared with azithromycin plus ceftriaxone combination therapy in the treatment of community-acquired pneumonia. Results The efficacy rate was 96.4% in moxifloxacin group and 90.0% in the control group. Bacterial clearance rate in the two groups was 6/7 and 5/5, respectively. The difference between groups was not statistically significant （P〉0. 05）. The time to defervescence to 37. 5 ℃ and hospital stay in moxifloxacin group [（3.2 ± 1.5） d and （8.2 ± 7.0） d] were shorter than those in the control group [（4. 4 ± 1.7） d and （10.0 ± 8.4） d]（P〈0.05）. The incidence of adverse drug reactions was 14. 3% in moxifloxacin group and 26.7% in the control group. The difference was not statistically significant between the two groups （P〈0. 05）. Conclusions Efficacy of moxifloxacin monotherapy is e quivalent to azithromycin plus ceftriaxone combination therapy in the treatment of Mycoplasma pneumonia. Moxifloxacin is better than the control therapy in terms of time to ddervescence and hospital stay.